Constitutively activated NF-κB pathway protects the malignant cells from apoptosis and confers resistance to chemotherapy.11, 12 Aberrant NF-κB activation is noted in various human lymphoma malignances,13, 14, 15, 16 including DLBCL and BL.17, 18, 19 Thus, NF-κB is a potential target for anti-lymphoid malignancy drug discovery. This evidence concerns the gene NFKB1 and Burkitt lymphoma.